Primary oral etoposide therapy in gestational trophoblastic disease: An update

Abstract

Sixty patients who developed persistent or metastatic gestational trophoblastic disease (GTD) received primary oral etoposide therapy (VP 16–213). Twelve patients had metastatic GTD. Fifty‐nine patients achieved biochemical remission. One patient had marked nausea and vomiting and the therapy was switched to a methotrexate/folinic acid regimen. Three patients developed relapse of GTD, giving a relapse rate of 5.1%. Etoposide is an active drug against choriocarcinoma. Its use should not be restricted to drug‐resistant GTD. Cancer 58:14–17, 1986. Copyright © 1986 American Cancer Society